Streptococcus pneumoniae: Difference between revisions
imported>Troy Wong |
mNo edit summary |
||
| (39 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{subpages}} | ||
{{Taxobox | |||
== | | color = pink | ||
| name = ''Streptococcus pneumoniae'' | |||
| image = Streptococcus pneumoniae.jpg|thumb|{{#ifexist:Template:Streptococcus pneumoniae.jpg/credit|{{Streptococcus pneumoniae.jpg/credit}}<br/>|}}Electron microscope photomicrograph of Streptococcus pneumoniae | |||
| regnum = [[Bacteria]] | |||
= | | phylum = [[Firmicutes]] | ||
| classis = [[Diplococci]] | |||
| ordo = [[Lactobacillales]] | |||
| familia = [[Streptococcaceae]] | |||
| genus = [[Streptococcus]] | |||
| species = [[Streptococcus]] | |||
| binomial = ''Streptococcus pneumoniae'' | |||
| binomial_authority = | |||
}} | |||
= | [[Image:.]] | ||
==Description and significance== | ==Description and significance== | ||
Streptococcus pneumoniae, also called pneumococcus, is a [[Gram-positive]], [[pathogenic]] bacterium capable of causing numerous infections. It the most common cause of [[pneumonia]] and [[bacterial meningitis]], and is commonly found in the upper [[respiratory tract]] of humans. ''S. pneumoniae'' is shaped like a lancet, a type of knife with a short wide two-edged blade. It is alpha [[hemolytic]] (a classification method using the breakdown of [[red blood cells]]) and is usually between 0.5 and 1.25 micrometers in size.<ref>[http://www.medterms.com/script/main/art.asp?articlekey=11270 Medicinenet: Streptococcus pneumoniae]</ref><ref>[http://www.textbookofbacteriology.net/S.pneumoniae.html Textbook of Bacteriology: Streptococcus pneumoniae]</ref> | |||
''S. pneumoniae'' was first isolated in 1881 simultaneously by U.S. Army physician [[George Sternberg]] and French chemist [[Louis Pasteur]]. ''S. pneumoniae'' has been used to prove that genetic material consists of [[DNA]]. In 1928 [[Frederick Griffith]] co-inoculated live pneumococci into a mouse along with heat-killed, virulent pneumococci. The live, harmless pneumococci were transformed into the lethal form. In 1944 [[Oswald Avery]], [[Colin MacLeod]] and [[Maclyn McCarty]] found that the transforming factor in Griffith's experiment was DNA. <ref>{{citation | |||
| title = The Great Influenza: The Epic Story of the Deadliest Plague In History | |||
''S. pneumoniae'' was first isolated in 1881 simultaneously by U.S. Army physician George Sternberg and French chemist Louis Pasteur. | | author = John M. Barry | publisher = Viking | year =2004}}</ref> | ||
==Genome structure== | ==Genome structure== | ||
''S. pneumoniae'' has a 2,160,837 base pair genome sequence. Its chromosome is circular and has 2236 coding regions. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. ''S. pneumoniae'' has shown a significant increase in antibiotic resistance over the past few decades, due to its rapid growth rate and genetic rearrangements. | ''S. pneumoniae'' has a 2,160,837 base pair [[genome sequence]]. Its [[chromosome]] is circular and has 2236 [[coding regions]]. Approximately 5% of the genome is composed of [[insertion sequences]] that may contribute to [[genome rearrangements]] through uptake of foreign DNA. ''S. pneumoniae'' has shown a significant increase in [[antibiotic resistance]] over the past few decades, due to its rapid growth rate and genetic rearrangements.<ref>[http://cmr.tigr.org/tigr-scripts/CMR/GenomePage.cgi?org=bsp Streptococcus pneumoniae TIGR4 Genome Page]</ref><ref>[http://www.textbookofbacteriology.net/S.pneumoniae.html Textbook of Bacteriology: Streptococcus pneumoniae]</ref> | ||
==Cell structure and metabolism== | ==Cell structure and metabolism== | ||
''S. pneumoniae'' is completely surrounded by a capsule made up of polysaccharides. The capsule interferes with phagocytosis by preventing opsonization of its cells. The cell wall of ''S. pneumoniae'' is six layers thick and made up of peptidoglycan with teichoic and lipoteichoic acids. Within these acids are choline-binding proteins (CBPs), which adhere to choline receptors on human cells. ''S. pneumoniae'' has pili, which are hair-like structures extending from its surface. It also has more than 500 surface proteins, including five penicillin binding proteins (PBPs), two neuraminidases, an IgA protease, as well as choline-binding proteins as stated previously. | ''S. pneumoniae'' is completely surrounded by a [[capsule]] made up of [[polysaccharides]]. The capsule interferes with [[phagocytosis]] by preventing [[opsonins|opsonization]] of its cells. The cell wall of ''S. pneumoniae'' is six layers thick and made up of [[peptidoglycan]] with [[teichoic]] and lipoteichoic acids. Within these acids are [[choline-binding proteins]] (CBPs), which adhere to choline receptors on human cells. ''S. pneumoniae'' has [[pili]], which are hair-like structures extending from its surface. It also has more than 500 surface proteins, including five [[penicillin binding proteins]] (PBPs), two [[neuraminidases]], an IgA [[protease]], as well as choline-binding proteins as stated previously.<ref>[http://www.textbookofbacteriology.net/S.pneumoniae.html Textbook of Bacteriology: Streptococcus pneumoniae]</ref> | ||
''S. pneumoniae'' gains a substantial amount of carbon and nitrogen using extracellular enzyme systems which allow for the metabolism of polysaccharides and hexosamines. These systems also damage host tissues and facilitate colonization. | ''S. pneumoniae'' gains a substantial amount of carbon and nitrogen using [[extracellular enzyme systems]] which allow for the metabolism of polysaccharides and [[hexosamines]]. These systems also damage host tissues and facilitate colonization.<ref>[http://www.textbookofbacteriology.net/S.pneumoniae.html Textbook of Bacteriology: Streptococcus pneumoniae]</ref> | ||
==Ecology== | ==Ecology== | ||
''S. pneumoniae'' is commonly found in the upper respiratory tract of humans, specifically the nasopharynx region. It is found in 5-10% of healthy adults, and 20-40% of healthy children | ''S. pneumoniae'' is commonly found in the [[upper respiratory tract]] of humans, specifically the [[nasopharynx]] region. It is found in 5-10% of healthy adults, and 20-40% of healthy children, and is non-pathogenic unless it travels outside this area, with area-specific presentations of infection. | ||
''S. pneumoniae'' sometimes shares its normal habitat with the pathogen Haemophilus influenzae. Individually each pathogen thrives on its own. However, when both pathogens inhabit the region at the same time, after 2 weeks only ''H. influenzae'' survives. Immune response caused by ''H. influenzae'' leads to the death of S. pneumoniae. | ''S. pneumoniae'' sometimes shares its normal habitat with the pathogen [[Haemophilus influenzae]]. Individually each pathogen thrives on its own. However, when both pathogens inhabit the region at the same time, after 2 weeks only ''H. influenzae'' survives. Immune response caused by ''H. influenzae'' leads to the death of S. pneumoniae. | ||
==Pathology== | ==Pathology== | ||
Depending on where ''S. pneumoniae'' travels, different infections will occur. If it reaches the Eustachian tube or nasal sinuses, otitis media and sinusitis will result. If it enters the lungs, pneumonia will occur. If ''S. pneumoniae'' enters the bloodstream, bacteremia will occur and can subsequently result in meningitis, brain abscess, septic arthritis, or osteomyelitis. ''S. pneumoniae'' most commonly causes pneumonia and meningitis. Symptoms of pneumonia are cough producing green or yellow sputum, chills, chest pain, fever, and difficulty breathing. Symptoms of meningitis are severe headache, neck stiffness, and fever. | Depending on where ''S. pneumoniae'' travels, different infections will occur. If it reaches the [[Eustachian tube]] or [[nasal sinuses]], [[otitis media]] and [[sinusitis]] will result. If it enters the lungs, [[pneumonia]] will occur. If ''S. pneumoniae'' enters the bloodstream, [[bacteremia]] will occur and can subsequently result in [[meningitis]], [[brain abscess]], [[septic arthritis]], or [[osteomyelitis]]. ''S. pneumoniae'' most commonly causes pneumonia and meningitis. Symptoms of pneumonia are cough producing green or yellow sputum, chills, chest pain, fever, and difficulty breathing. Symptoms of meningitis are severe headache, neck stiffness, and fever.<ref> | ||
[http://www.who.int/vaccine_research/diseases/ari/en/index5.html World Health Organization: Streptococcus pneumoniae]</ref> | |||
''S. pneumoniae'' has several virulence factors which enable it to evade the human immune system. It has a polysaccharide capsule, which interferes with phagocytosis by preventing opsonization of its cells. It has pneumolysin, a protein that causes lysis of host cells and prevents activation of the complement pathway. It also has autolysin, which lyses its own cells to release its contents. Other virulence factors include hydrogen peroxide, pili, and choline binding protein. | ''S. pneumoniae'' has several [[virulence factors]] which enable it to evade the human immune system. It has a polysaccharide capsule, which interferes with phagocytosis by preventing opsonization of its cells. It has [[pneumolysin]], a protein that causes [[lysis]] of host cells and prevents activation of the [[complement pathway]]. It also has [[autolysin]], which lyses its own cells to release its contents. Other virulence factors include [[hydrogen peroxide]], pili, and choline binding protein.<ref>[http://www.textbookofbacteriology.net/S.pneumoniae.html Textbook of Bacteriology: Streptococcus pneumoniae]</ref> | ||
== | ==Vaccination== | ||
{{main|Pneumococcal vaccine}} | |||
The reason it is difficult to pinpoint a vaccination is due to the fact that over 90 [[serotypes]] of ''S. pneumoniae'' exist, and that immunization with a one serotype does not protect against infection with other serotypes. Vaccinations currently in use target multiple serotypes. Young children (under 60 months) are given a [[heptavalent pneumococcal conjugate vaccine]] (PCV 7) such as [[Prevnar]]. | |||
A recent study showed that a pneumococcal conjugate vaccine introduced in children in the year 2000 showed a significant decrease in effect after 4 years. The 7-Valent pneumococcal conjugate vaccine (PCV7) was introduced in children in 2000, and the proportion of ''S. pneumoniae'' isolates susceptible to the antibiotic was tested yearly. After 4 years, the proportion of susceptible isolates decreased significantly, showing that ''S. pneumoniae'' builds resistance to antibiotics fairly rapidly.<ref>[http://www.pidj.org/pt/re/pidj/abstract.00006454-200702000-00005.htm;jsessionid=Hy6b2gW3FchRfm2P1KSXJGdl4FLDs895xbvPXPMn39yppzs2JQPh!1569501743!181195629!8091!-1 Farrell, D., Klugman, K., Pichichero, M. "Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States". ''Pediatric Infectious Disease Journal''. February 2007. Vol. 26. p. 123-128.]</ref> | |||
''S. pneumoniae'' vaccines are typically injected into the body, however a study conducted research using vaccines administered using the [[intranasal]] route had successful results in animals. Using unencapsulated killed whole-cell pneumococci of the type 6B strain, researchers administered the vaccine intranasally into rats. The vaccine proved protect the animal from infection.<ref>[http://iai.asm.org/cgi/content/full/69/8/4870 Malley, R., Lipsitch, M., Stack, A., Saladino, R., Fleisher, G., Pelton, S., Thompson, C., Briles, D., and Anderson, P. "Intranasal Immunization with Killed Unencapsulated Whole Cells Prevents Colonization and Invasive Disease by Capsulated Pneumococci". ''Infection and Immunity''. August 2001. Vol. 69. p. 4870-4873.]</ref> | |||
==Current research== | |||
New serotypes are still being discovered. A recent study found a new capsular serotype of ''S. pneumoniae''. Researchers found a new subtype within serotype 6. Two subtypes (A & B) were already known, however a subtype C has now been discovered. This study showed that serotypes can be found within already established serotypes.<ref>[http://jcm.asm.org/cgi/content/abstract/45/4/1225 Park, I., Pritchard, D., Cartee, R., Brandao, A., Brandileone, M., and Nahm, M. "Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae". ''Journal of Clinical Microbiology''. April 2007. Vol. 45. p. 1225-1233.]</ref> | |||
'' | |||
==References== | ==References== | ||
{{reflist}}[[Category:Suggestion Bot Tag]] | |||
[ | |||
[ | |||
Latest revision as of 16:01, 22 October 2024
| Streptococcus pneumoniae | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | ||||||||||||||
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Streptococcus pneumoniae |
[[Image:.]]
Description and significance
Streptococcus pneumoniae, also called pneumococcus, is a Gram-positive, pathogenic bacterium capable of causing numerous infections. It the most common cause of pneumonia and bacterial meningitis, and is commonly found in the upper respiratory tract of humans. S. pneumoniae is shaped like a lancet, a type of knife with a short wide two-edged blade. It is alpha hemolytic (a classification method using the breakdown of red blood cells) and is usually between 0.5 and 1.25 micrometers in size.[1][2]
S. pneumoniae was first isolated in 1881 simultaneously by U.S. Army physician George Sternberg and French chemist Louis Pasteur. S. pneumoniae has been used to prove that genetic material consists of DNA. In 1928 Frederick Griffith co-inoculated live pneumococci into a mouse along with heat-killed, virulent pneumococci. The live, harmless pneumococci were transformed into the lethal form. In 1944 Oswald Avery, Colin MacLeod and Maclyn McCarty found that the transforming factor in Griffith's experiment was DNA. [3]
Genome structure
S. pneumoniae has a 2,160,837 base pair genome sequence. Its chromosome is circular and has 2236 coding regions. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. S. pneumoniae has shown a significant increase in antibiotic resistance over the past few decades, due to its rapid growth rate and genetic rearrangements.[4][5]
Cell structure and metabolism
S. pneumoniae is completely surrounded by a capsule made up of polysaccharides. The capsule interferes with phagocytosis by preventing opsonization of its cells. The cell wall of S. pneumoniae is six layers thick and made up of peptidoglycan with teichoic and lipoteichoic acids. Within these acids are choline-binding proteins (CBPs), which adhere to choline receptors on human cells. S. pneumoniae has pili, which are hair-like structures extending from its surface. It also has more than 500 surface proteins, including five penicillin binding proteins (PBPs), two neuraminidases, an IgA protease, as well as choline-binding proteins as stated previously.[6]
S. pneumoniae gains a substantial amount of carbon and nitrogen using extracellular enzyme systems which allow for the metabolism of polysaccharides and hexosamines. These systems also damage host tissues and facilitate colonization.[7]
Ecology
S. pneumoniae is commonly found in the upper respiratory tract of humans, specifically the nasopharynx region. It is found in 5-10% of healthy adults, and 20-40% of healthy children, and is non-pathogenic unless it travels outside this area, with area-specific presentations of infection.
S. pneumoniae sometimes shares its normal habitat with the pathogen Haemophilus influenzae. Individually each pathogen thrives on its own. However, when both pathogens inhabit the region at the same time, after 2 weeks only H. influenzae survives. Immune response caused by H. influenzae leads to the death of S. pneumoniae.
Pathology
Depending on where S. pneumoniae travels, different infections will occur. If it reaches the Eustachian tube or nasal sinuses, otitis media and sinusitis will result. If it enters the lungs, pneumonia will occur. If S. pneumoniae enters the bloodstream, bacteremia will occur and can subsequently result in meningitis, brain abscess, septic arthritis, or osteomyelitis. S. pneumoniae most commonly causes pneumonia and meningitis. Symptoms of pneumonia are cough producing green or yellow sputum, chills, chest pain, fever, and difficulty breathing. Symptoms of meningitis are severe headache, neck stiffness, and fever.[8]
S. pneumoniae has several virulence factors which enable it to evade the human immune system. It has a polysaccharide capsule, which interferes with phagocytosis by preventing opsonization of its cells. It has pneumolysin, a protein that causes lysis of host cells and prevents activation of the complement pathway. It also has autolysin, which lyses its own cells to release its contents. Other virulence factors include hydrogen peroxide, pili, and choline binding protein.[9]
Vaccination
The reason it is difficult to pinpoint a vaccination is due to the fact that over 90 serotypes of S. pneumoniae exist, and that immunization with a one serotype does not protect against infection with other serotypes. Vaccinations currently in use target multiple serotypes. Young children (under 60 months) are given a heptavalent pneumococcal conjugate vaccine (PCV 7) such as Prevnar.
A recent study showed that a pneumococcal conjugate vaccine introduced in children in the year 2000 showed a significant decrease in effect after 4 years. The 7-Valent pneumococcal conjugate vaccine (PCV7) was introduced in children in 2000, and the proportion of S. pneumoniae isolates susceptible to the antibiotic was tested yearly. After 4 years, the proportion of susceptible isolates decreased significantly, showing that S. pneumoniae builds resistance to antibiotics fairly rapidly.[10]
S. pneumoniae vaccines are typically injected into the body, however a study conducted research using vaccines administered using the intranasal route had successful results in animals. Using unencapsulated killed whole-cell pneumococci of the type 6B strain, researchers administered the vaccine intranasally into rats. The vaccine proved protect the animal from infection.[11]
Current research
New serotypes are still being discovered. A recent study found a new capsular serotype of S. pneumoniae. Researchers found a new subtype within serotype 6. Two subtypes (A & B) were already known, however a subtype C has now been discovered. This study showed that serotypes can be found within already established serotypes.[12]
References
- ↑ Medicinenet: Streptococcus pneumoniae
- ↑ Textbook of Bacteriology: Streptococcus pneumoniae
- ↑ John M. Barry (2004), The Great Influenza: The Epic Story of the Deadliest Plague In History, Viking
- ↑ Streptococcus pneumoniae TIGR4 Genome Page
- ↑ Textbook of Bacteriology: Streptococcus pneumoniae
- ↑ Textbook of Bacteriology: Streptococcus pneumoniae
- ↑ Textbook of Bacteriology: Streptococcus pneumoniae
- ↑ World Health Organization: Streptococcus pneumoniae
- ↑ Textbook of Bacteriology: Streptococcus pneumoniae
- ↑ Farrell, D., Klugman, K., Pichichero, M. "Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States". Pediatric Infectious Disease Journal. February 2007. Vol. 26. p. 123-128.
- ↑ Malley, R., Lipsitch, M., Stack, A., Saladino, R., Fleisher, G., Pelton, S., Thompson, C., Briles, D., and Anderson, P. "Intranasal Immunization with Killed Unencapsulated Whole Cells Prevents Colonization and Invasive Disease by Capsulated Pneumococci". Infection and Immunity. August 2001. Vol. 69. p. 4870-4873.
- ↑ Park, I., Pritchard, D., Cartee, R., Brandao, A., Brandileone, M., and Nahm, M. "Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus pneumoniae". Journal of Clinical Microbiology. April 2007. Vol. 45. p. 1225-1233.